Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions

Background: In this study, we investigated the efficacy of continuous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients harboring favorable mutations regarding the progressive disease (PD) status with appearance of indolent new l...

Full description

Bibliographic Details
Main Authors: Ping-Chih Hsu, Li-Chung Chiu, Shih-Hong Li, Chih-Hung Chen, Chih-Liang Wang, Kuo-Chin Kao, John Wen-Chang Chang, Chih-Wei Wang, Chih-Teng Yu, Fu-Tsai Chung, Cheng-Ta Yang, Chien-Ying Liu
Format: Article
Language:English
Published: Elsevier 2016-04-01
Series:Biomedical Journal
Subjects:
Epidermal growth factor receptor-tyrosine kinase inhibitor
Overall survival
Progression-free survival
Progressive disease
Response Evaluation Criteria in Solid Tumors
Online Access:http://www.sciencedirect.com/science/article/pii/S2319417016300683

Internet

http://www.sciencedirect.com/science/article/pii/S2319417016300683

Similar Items